Journal
INTERNAL MEDICINE
Volume 58, Issue 22, Pages 3261-3265Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.2988-19
Keywords
small cell lung cancer; epidermal growth factor receptor; adenocarcinoma; transcriptional alteration; acquired drug resistance
Categories
Ask authors/readers for more resources
Small cell lung cancer (SCLC) transformation of epidermal growth factor receptor (EGFR) mutant adenocarcinoma (ADC) during EGFR tyrosine kinase inhibitor (TKI) treatment is an example of a rare subset of acquired drug resistance. We herein report the case of a 75-year-old man treated with afatinib who was then diagnosed with SCLC transformation. After two years of successful treatment with afatinib, the tumor relapsed, and a re-biopsy revealed SCLC harboring EGFR exon 19 deletion. We encountered a case of transcriptional alteration, potentially important for SCLC transformation of EGFR mutant lung ADC, that was recognized via the expression of NOTCH, ASCL1 and RB1 on immunohistochemical staining.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available